Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area

por SILVERBERG, Jonathan I., TALLMAN, Anna M., PORTS, William C., GERBER, Robert A., TAN, Huaming, ZIELINSKI, Michael A.
Publicado 2020

Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years

por Luger, Thomas A., Hebert, Adelaide A., Zaenglein, Andrea L., Silverberg, Jonathan I., Tan, Huaming, Ports, William C., Zielinski, Michael A.
Publicado 2022

Tolerability of Topical Treatments for Atopic Dermatitis

por Draelos, Zoe D., Feldman, Steven R., Berman, Brian, Olivadoti, Melissa, Sierka, Debra, Tallman, Anna M., Zielinski, Michael A., Ports, William C., Baldwin, Sheryl
Publicado 2019

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups

por Callender, Valerie D., Alexis, Andrew F., Stein Gold, Linda F., Lebwohl, Mark G., Paller, Amy S., Desai, Seemal R., Tan, Huaming, Ports, William C., Zielinski, Michael A., Tallman, Anna M.
Publicado 2019